Commonwealth Equity Services LLC Has $150,000 Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Commonwealth Equity Services LLC cut its holdings in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 36.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 49,333 shares of the biopharmaceutical company’s stock after selling 28,708 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Revance Therapeutics were worth $150,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of RVNC. Charles Schwab Investment Management Inc. raised its holdings in Revance Therapeutics by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 790,837 shares of the biopharmaceutical company’s stock valued at $4,104,000 after acquiring an additional 41,250 shares in the last quarter. FMR LLC increased its position in shares of Revance Therapeutics by 28.6% during the third quarter. FMR LLC now owns 214,596 shares of the biopharmaceutical company’s stock valued at $1,114,000 after purchasing an additional 47,768 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Revance Therapeutics by 11.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 265,210 shares of the biopharmaceutical company’s stock valued at $1,376,000 after purchasing an additional 27,420 shares in the last quarter. State Street Corp lifted its position in Revance Therapeutics by 6.6% in the third quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock worth $12,632,000 after purchasing an additional 150,323 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in Revance Therapeutics during the third quarter worth $2,315,000. 97.70% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on RVNC shares. Barclays lowered their target price on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Monday, December 23rd. StockNews.com assumed coverage on Revance Therapeutics in a report on Friday. They issued a “hold” rating for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Revance Therapeutics currently has a consensus rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Stock Performance

NASDAQ RVNC opened at $3.65 on Friday. The stock has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. Revance Therapeutics, Inc. has a 52 week low of $2.30 and a 52 week high of $6.65. The stock’s 50 day moving average price is $3.65 and its two-hundred day moving average price is $3.98.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.